| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | 20% YoY increase to 384 Cr total revenue. |
|---|---|
| Margins | EBITDA margin at 17%; 180 bps improvement QoQ. |
| Demand visibility | Strong momentum in base business supported by new pipeline. |
| Management confidence | Balanced; optimistic on base business, cautious on Ibuprofen headwinds. |
Growth
Revenue grew 20% YoY to 384 Cr, driven by strong 24% base business growth.
Outlook
Management targeting 10% base business growth and becoming net-debt-free by FY29.
Risks
Ibuprofen remains loss-making with -12% margins; West Asia crisis creates supply chain vulnerability.
Last quarter's promises, checked
Delivered
- Debt reduction of 158 Cr → delivered 135 Cr + 113 Cr rights (= BEAT)
- Base business EBITDA margin 25% → delivered 26% (= BEAT)
- Q4 revenue momentum → delivered 20% YoY growth to 384 Cr (= BEAT)
Partly delivered
- Targeting debt-free by FY29 → reduced debt to ~503 Cr (= PARTIAL)
Missed
- Ibuprofen strategic options in 2 quarters → remains loss-making/unresolved (= MISS)
Earnings Call Transcript filed with BSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹739.15
- Market cap
- ₹3,552 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- -2192.7×Sector 50.4×
- Promoter holding
- 41.93%-0.07% QoQ
- FII holding
- 11.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Q1 FY27 Results: Net Profit ₹16.3 Cr, Up 55.2% YoY
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹381.6 Cr (+19.6% YoY) and net profit of ₹16.3 Cr (+55.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹16.3 Cr · +55.2% YoY
Solara Active Pharma Sciences Earnings Call: Key Takeaways
Solara delivered its highest Q4 revenue in 8 quarters at INR 392cr, driven by a strong base business with 54% gross margins, despite persistent headwinds and negative EBITDA in the Ibuprofen segment.
Solara Active Pharma Sciences Earnings Call: Key Takeaways
Solara's base business shows strong momentum, hitting eight-quarter highs in revenue and EBITDA, yet the Ibuprofen segment remains a significant drag, forcing a strategic review and potential divestment of the vertical.
Solara Active Pharma Sciences Q4 FY26 Results: Turns Profitable, Net Profit ₹9.6 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹387.3 Cr (+41.9% YoY) and net profit of ₹9.6 Cr for Q4 FY26.
- Key figure
- Net profit ₹9.6 Cr